Skip to main content

All cancer patients at Vanderbilt-Ingram will have the opportunity to ring the bell 

Submitted by vicc_news on

From his infusion chair, Matt Duckworth would clap and yell “woohoo” each time he heard another cancer patient ring the bell to mark the completion of chemotherapy treatment, even though he knew he would never get that opportunity. 

Matt Duckworth
Matt Duckworth

On Friday, April 25 — seven months after his death — the bell pealed loudly at the Vanderbilt-Ingram Cancer Center infusion clinic as a plaque was unveiled in his honor and the announcement was made that patients receiving palliative chemotherapy would also get to ring the bell going forward. 

Duckworth was in the prime of his life at age 41, working as director of Population Health Operations for Vanderbilt Health Affiliated Network and doting on his three dogs with his wife, Suzanne, when he was diagnosed in 2020 with Stage 4 gastroesophageal cancer that had metastasized to his liver.  Although the chemotherapy didn’t cure his cancer, the treatments did extend his life for four years. 

“Matt had infusions weekly, and as we were sitting in the infusion room for hours at a time, we would hear the bell ring, and we would hear everybody clapping,” said Suzanne Duckworth. “He would clap and yell, ‘Woohoo!’ He just emitted such a positive vibe and aura. I would sit there and think, ‘He’s never going to get that because he has terminal cancer.’ Now, that thought might have come into his brain, but you would never know it because he never said it.” 

Suzanne Duckworth consoles her mother-in-law, Betsye Duckworth, as Stephanie Broderick, who worked with Matt Duckworth, reads words of appreciation from his colleagues. (photo by Susan Urmy)
Suzanne Duckworth consoles her mother-in-law, Betsye Duckworth, as Stephanie Broderick, who worked with Matt Duckworth, reads words of appreciation from his colleagues. (photo by Susan Urmy)

She asked Vanderbilt-Ingram about adding a plaque, and a ceremony was held in Matt’s memory to mark the occasion. Colleagues, family and friends shared stories about the man, who was beloved for his sense of humor, love for trips to Disney World and his affinity for dogs. His physician, Michael Gibson, MD, PhD, associate professor of Medicine, spoke about the relationship he developed with Matt and how much he enjoyed spending time with him.  

Suzanne Duckworth stated, “This is for you, Matt,” and rang the bell. 

His mother, Betsye, stood nearby wiping away a tear. On the plaque that had just been unveiled was a poem written by his sister, Jill Comfort.

I stand before the bell today 

Not for an end, but to proudly say 

I fought with every breath I had  

Through days of pain and times of glad 

I ring this bell for all I’ve done 

For every battle, fought and won 

For every day, for every try 

I ring the bell — head held high 

Ten years younger than Matt, Comfort had come to Nashville from Mississippi, to help Suzanne, who is a Vanderbilt nurse, with her big brother when he began hospice care. It had also bothered her that Matt never got to ring that bell, so she bought him one and read him the poem she had written.  

“But he wouldn’t ring the bell because that was admitting defeat,” Suzanne Duckworth said. 

A native of Clinton, Mississippi, Matt excelled in life, attaining an undergraduate degree in journalism, a Master of Science in public relations and then a Juris Doctor from Mississippi College of Law with honors followed by a Doctor of Healthcare Administration.  

He and Suzanne married in 2003 and eventually moved to Nashville, where they both established careers at Vanderbilt University Medical Center.  

“When things were running down, he didn’t want to give up,” Comfort said. “Then one day, he asked me if I would read the poem at his funeral and ring the bell. That somehow transpired into where we are today. We talked about how there were other people in his situation that don’t get that opportunity who are needing treatments for years and years. They need some encouragement.” 

Suzanne Duckworth approached Julie Bulger, manager of Patient- and Family-Centered Care at Vanderbilt-Ingram about allowing any chemotherapy patient to ring the bell regardless of whether they had completed treatment or achieved remission. 

“When Suzanne shared her idea about a new plaque, I deeply appreciated what she said, how when Matt heard the bell, he felt happy for those who rang it,” Bulger said. “It is rung traditionally at the end of treatment, but many patients may never have that opportunity. This thought comes from a lot of places, not only from Matt, but Suzanne articulated it so beautifully.  I believe this is going to resonate with many people.

“The bell can be rung at any time. It doesn’t have to be the last day of treatment. It can be rung because you’re having a bad day, and you’re fighting, and it’s hard. Or you have achieved a different milestone. You want to ring that bell because it’s going to mean something for you, and you want to feel uplifted,” Bulger said.

The post All cancer patients at Vanderbilt-Ingram will have the opportunity to ring the bell  appeared first on VUMC News.

Vanderbilt-Ingram 26th Annual Scientific Symposium focuses on AI 

Submitted by vicc_news on

Experts on the research, clinical use, governance and ethical use of artificial intelligence gathered for the recent Vanderbilt-Ingram Cancer Center 26th Annual Scientific Symposium. 

In a twist from years past, graduate students and postdoctoral fellows took the helm in selecting the topics and inviting speakers focused on “Artificial Intelligence in Cancer Research and Clinical Care.”

The keynote speakers were Eytan Ruppin, MD, PhD, chief of the Cancer Data Science Laboratory at the National Cancer Institute, and Gelareh Zadeh, MD, PhD, chair of the Department of Neurologic Surgery at Mayo Clinic.  

Ruppin detailed how he is developing computational approaches for advancing precision oncology, and Zadeh explained how she is using integrated multi-platform molecular analysis of brain tumors to predict patients’ responses to targeted therapies. Ruppin participated in panel discussions about artificial intelligence. 

“I am enriched talking to you guys,” Ruppin said. “I develop AI materials, but I am not using them to treat patients. I am learning a lot.” 

Douglas Flora, MD, executive medical director of Oncology Services at the Yung Family Cancer Center at St. Elizabeth in Edgewood, Kentucky, and the editor-in-chief of AI in Precision Oncology, replied, “All of us are cross pollinating. That’s why I love a symposium like this.” 

In opening the first panel discussion that focused on ethics, Ellen Wright Clayton, MD, JD, the Craig-Weaver Professor of Pediatrics, professor of Law and professor of Health Policy at Vanderbilt, framed artificial intelligence from an historical perspective, noting that “decision support is not new to medicine.” She gave specific examples of how clinicians can use artificial intelligence for decision support but stressed that they should not rely solely on it for treatment plans. 

“It is not OK simply to get the AI output and just do what it says,” Clayton said. “Maybe it is OK, but it is always required to see if that’s the right advice. Always.” 

In another twist from years past, the Mission Moment, which is a personal testament from a patient, was presented by a pediatric cancer survivor for the first time. Easton Reeder, 13, who has undergone surgery and chemotherapy for pilocytic astrocytoma — a type of brain tumor — shared about his experiences living with cancer. He told his story vividly with flashes of humor, describing how being tossed in the air like a rodeo clown by a Great Dane led to his diagnosis.

Clinicians initially concluded that he had a concussion because of persistent headaches that followed, but his mother, who is a nurse, insisted on a brain scan. Reeder, a committed athlete, who continued playing sports even while undergoing chemotherapy, was given a jersey signed by Vanderbilt baseball players.

“I learned that tomorrow isn’t a promise, and I have to make the best of every moment I have,” Reeder said. “I also learned that there is no ‘normal button.’ I have been trying to learn that power since forever, until I realized that power is not to be . . . God has proven to me that anything is possible through him.” 

In his welcoming remarks, Vanderbilt-Ingram director Ben Ho Park, MD, PhD, emphasized the importance of training new generations of cancer researchers and clinicians. 

“This is an opportunity for us to celebrate all the cancer research going on at Vanderbilt-Ingram,” Park said. “For all of you who don’t know, we really run the spectrum of everything research: clinical, population science, laboratory science and everything in between. This is our time of the year when we get to showcase and highlight not only the great science that our external panelists and presenters are going to bring — but you will be duly impressed, as I always am, by what our trainees bring to the table. The future really is bright, and we have to keep sustaining our future by encouraging and mentoring the next generation, which will ultimately lead to more cures.” 

From left are Christopher Williams, MD, PhD, associate director of Research Education at VICC, Michael Robinson, MD; Guochong “Damon” Jia, PhD, postdoctoral scholar of the year, Katie Brown, PhD, co-chair of the Vanderbilt-Ingram Scientific Symposium, Candace Grisham, MS, co-graduate student of the year, Xiaopeng Sun, PhD, co-graduate student of the year, Jared Rhodes, co-chair of the Scientific Symposium, Ben Ho Park, MD, PhD, director of VICC. (photo by Donn Jones)
From left are Christopher Williams, MD, PhD, associate director of Research Education at VICC, Michael Robinson, MD; Guochong “Damon” Jia, PhD, postdoctoral scholar of the year, Katie Brown, PhD, co-chair of the Vanderbilt-Ingram Scientific Symposium, Candace Grisham, MS, co-graduate student of the year, Xiaopeng Sun, PhD, co-graduate student of the year, Jared Rhodes, co-chair of the Scientific Symposium, Ben Ho Park, MD, PhD, director of VICC. (photo by Donn Jones)

Two tied in voting for the Graduate Student of the Year. Candace Grisham, MS, received the honor for her research into brain tumors, including a study she authored that was published in Clinical Neurology and Neurosurgery. Xiaopeng Sun, PhD, is the other co-awardee for his research into biomarkers to predict immunotherapy outcomes in patients, and his prolific contributions to that field of study, including 12 studies published in scientific journals. 

Guochong “Damon” Jia, PhD, MPH, is the Postdoctoral Scholar of the Year. He was selected for his high-impact research that has advanced the understanding of cancer genetics and epidemiology, including the largest genetic study ever conducted on breast cancer in African ancestry populations, which was published in Nature Genetics

The poster exhibition was one of the largest ever for the annual event. Sarah Reed took home the overall winner award for her entry “Identifying Genotype-Specific Effects of CHIP on Solid Tumors Using Chimeric Mouse Modeling and Clinical Data.” 

In the Translational Science Category, Julia Steele won first place; Alexander Kwiatkowski, PhD, won second place; Heather Beasley, PhD, won third place; and honorable mention went to Jacey Marshall. 

Robust participation in the Basic Science Category resulted in duplicate prizes due to the number of entries. Rachel Sinard and Lincoln Brown won first place prizes. Emily Green and Logan Vlach received second place awards, andAnna Gilbert and Alyssa Jarabek received third place awards. Honorable mentions went to Sydney Bates, Nicholas Eleuteri, Sarah Glass, PhD, Gabriela Gonzalez Vasquez, Maxwell Hamilton, Yash Pershad, Jared Rhodes and Brenda Rios. 

In the Population Science Category, Michael Betti received first place; Duc Huy Le, MD, MBA, received second place; and there was a tie for third place with Melissa Goldin and Jiajun Shi, PhD, both receiving awards. Honorable mention went to Grace Xu. 

The post Vanderbilt-Ingram 26th Annual Scientific Symposium focuses on AI  appeared first on VUMC News.

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened.

Three Vanderbilt-affiliated cellular therapy programs receive reaccreditation

Submitted by vicc_news on

The cellular therapy programs at Vanderbilt-Ingram Cancer Center, Monroe Carell Jr. Children’s Hospital at Vanderbilt, and the VA Tennessee Valley Healthcare System have received reaccreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).

Founded in 1995, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a nonprofit corporation co-founded by the International Society for Cell and Gene Therapy and the American Society for Transplantation and Cellular Therapy for the purposes of voluntary inspection and accreditation in the field of cellular therapy.

“FACT is an internationally recognized accrediting body for hospitals that offer stem cell transplant and cellular therapy, and recognition by FACT indicates that the accredited institution has met the most rigorous standard in every aspect of cellular therapy,” said Adetola Kassim, MD, professor of Medicine and director of the Vanderbilt Stem Cell Transplant and Cellular Therapy Program. “This covers the entire spectrum of stem cell therapy from clinical care to donor management, cell collection, processing, storage, transplant, administration and cell release.”

The Vanderbilt and VA Tennessee Valley Healthcare System programs received accreditation notification on April 14 after on-site inspections in October 2024. The accreditation is effective for three years.

“Congratulations to the entire Vanderbilt University Medical Center and VA Tennessee Valley Healthcare System team on achieving FACT accreditation and providing quality care for the people we serve,” Kassim said.

The post Three Vanderbilt-affiliated cellular therapy programs receive reaccreditation appeared first on VUMC News.

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Kimberly Dahlman elected to board of International Association of Medical Science Educators 

Submitted by vicc_news on
Kimberly Dahlman, PhD
Kimberly Dahlman, PhD

Kimberly Dahlman, PhD, associate professor of Medicine in the Division of Hematology and Oncology, has been elected to the board of directors of the International Association of Medical Science Educators (IAMSE). 

Dahlman, who is the assistant director of Cancer Research Training and Education at Vanderbilt-Ingram Cancer Center, will begin serving her three-year term upon the closing of the association’s annual conference on June 17. She serves as co-director of the third- and fourth-year undergraduate medical education curriculum at Vanderbilt University School of Medicine and as co-director of the Research Education Core of the Meharry-Vanderbilt-Tennessee State University Cancer Partnership.

She is also director of the VERTICAL post-baccalaureate program, the V-EXCEL undergraduate cancer research program and the VISTO medical student research program at Vanderbilt-Ingram. Nationally, she is president of the Association of Biochemistry Educators.  

With more than 2,000 members, the IAMSE’s mission is to advance health profession education through teacher development and to ensure that the teaching and learning of medical science continues to be firmly grounded in foundational sciences and the best practices of teaching. 

The post Kimberly Dahlman elected to board of International Association of Medical Science Educators  appeared first on VUMC News.

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
Subscribe to